Delayed early antiretroviral treatment is associated with an HIV-specific long-term cellular response in HIV-1 vertically infected infants

Vaccine. 2008 Sep 19;26(40):5196-201. doi: 10.1016/j.vaccine.2008.03.062. Epub 2008 Apr 15.

Abstract

Antiviral T-cell immune responses appear to be crucial to control HIV replication. Infants treated before the third month of life with highly active antiretroviral treatment (HAART) did not develop a persistent HIV-specific immune response. We evaluated how delayed initiation of HAART after 3 months of age influences the development of HIV-1-specific T-cell responses during long-term follow-up in 9 HIV-1 vertically infected infants. These data suggest that a longer antigenic stimulation, due to a larger window for therapeutic intervention with HAART, is associated with the establishment of a persistent specific HIV immune response resulting in a long-term viral control of vertically infected infants.

MeSH terms

  • Amino Acid Sequence
  • Antiretroviral Therapy, Highly Active*
  • Drug Administration Schedule
  • HIV Infections / drug therapy*
  • HIV Infections / immunology*
  • HIV Infections / virology
  • HIV-1 / immunology*
  • Humans
  • Infant
  • Infectious Disease Transmission, Vertical*
  • Lymphocyte Activation
  • Molecular Sequence Data
  • Peptides / chemistry
  • T-Lymphocytes / immunology*
  • Treatment Outcome
  • gag Gene Products, Human Immunodeficiency Virus / chemistry
  • nef Gene Products, Human Immunodeficiency Virus / chemistry
  • tat Gene Products, Human Immunodeficiency Virus / chemistry

Substances

  • Peptides
  • gag Gene Products, Human Immunodeficiency Virus
  • nef Gene Products, Human Immunodeficiency Virus
  • tat Gene Products, Human Immunodeficiency Virus